News

Health Canada has approved Rexulti (brexpiprazole) for agitation associated with Alzheimer’s disease-related dementia in patients with aggressive behavior. The treatment, co-developed by Otsuka Pharmaceuticals and Lundbeck, was recently approved by the U.S. Food and Drug Administration (FDA) for the same indication. “Today marks a major milestone…

Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year,…

Biogen is discontinuing development and commercialization of its controversial Alzheimer’s disease treatment Aduhelm (aducanumab) — a move that’s “not related to any safety or efficacy concerns,” the company said in a press release. Instead, according to Christopher Viehbacher, president and CEO of Biogen, the company is…

A commercially available blood test, sold by ALZpath, can identify with high accuracy Alzheimer’s disease patients who are likely to be eligible for new treatments, a study suggests. By detecting a version of the tau protein in a blood sample, the “ALZpath pTau217 test can help healthcare providers…

The U.S. Food and Drug Administration (FDA) has approved BrainSee, Darmiyan’s software for predicting the likelihood that a person with mild cognitive impairment (MCI) will progress to Alzheimer’s disease-associated dementia. Darmiyan believes the technology will help to screen and identify high-risk patients early, enabling a prompt start…

Enrollment is now complete in the LIFT-AD clinical trial evaluating Athira Pharma‘s fosgonimeton, an experimental treatment for mild-to-moderate Alzheimer’s disease. The Phase 2/3 study (NCT04488419) enrolled about 315 participants, who received either 40 mg fosgonimeton or a placebo for 26 weeks (about six months). Top-line data is expected in…

A tool called focused ultrasound, or FUS, may be a safe and promising way to help antibody-based treatments better reach the brain, and clear away toxic amyloid-beta protein clumps (aggregates), in people with Alzheimer’s disease. The approach involves using targeted sound waves to temporarily open up the selective blood-brain…

The cell therapy candidate Lomecel-B significantly improved cognitive function and reduced brain volume loss relative to a placebo in a Phase 2a clinical trial of people with mild Alzheimer’s disease, according to new data announced by the treatment’s developer Longeveron. “We believe these new data may provide evidence…

A rare variant in the APOE gene, known as the Christchurch mutation or APOE3ch, can protect against the development of Alzheimer’s disease by stopping the spread of toxic clumps of the tau protein in the brain, a new study suggests. The findings may have implications for better understanding Alzheimer’s underlying…

A proof-of-concept Phase 2b clinical trial evaluating the safety and efficacy of Advantage Therapeutics’ investigational immunotherapy AD04 in people with mild Alzheimer’s disease has enrolled its first patient. The placebo-controlled study is being conducted in Austria, France, Poland, Bulgaria, and Slovakia, and is expected to open clinical sites in Germany and…